



Mylan N.V.
Investor Relations Department
PO Box 2648
Portland, OR 97208-2648
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: MYL

| | |
|---------------|----------------------------|
| Last Trade: | 30.72 |
| Trade Time: | 4:00 PM ET Aug 18, 2017 |
| Change: | 0.16 (+0.524%) |
| Day Range | 30.50 - 31.23 |
| 52-Week Range | 29.39 - 49.20 |
| Volume | 7,185,271 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 7,500 marketed products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Aug 17, 2017

[Mylan Finalizes Settlement Agreement on Medicaid Rebate Classification for EpiPen® Auto-Injector](#)

Aug 10, 2017

[Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada](#)

Aug 9, 2017

[Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance](#)

Aug 8, 2017

[Mylan Launches Avonza™ in India](#)

Aug 7, 2017

[Mylan Receives Tentative Approval for "TLD" Under PEPFAR](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

May 23, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 9, 2017

[Quarterly Report \(10-Q\)](#)

May 10, 2017

[Quarterly Report \(10-Q\)](#)